These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 38004288)

  • 21. Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane.
    Bertorello N; Luksch R; Bisogno G; Haupt R; Spallarossa P; Cenna R; Fagioli F
    Pediatr Blood Cancer; 2023 Jun; ():e30515. PubMed ID: 37355856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer.
    Varghese SS; Eekhoudt CR; Jassal DS
    Mol Cell Biochem; 2021 Aug; 476(8):3099-3109. PubMed ID: 33835331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree?
    Kalyanaraman B
    Redox Biol; 2020 Jan; 29():101394. PubMed ID: 31790851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anthracycline Associated Disturbances of Cardiovascular Homeostasis.
    Avagimyan A; Kakturskiy L; Heshmat-Ghahdarijani K; Pogosova N; Sarrafzadegan N
    Curr Probl Cardiol; 2022 May; 47(5):100909. PubMed ID: 34167841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine.
    Cheah IK; Tang RMY; Wang X; Sachaphibulkij K; Chong SY; Lim LHK; Wang JW; Halliwell B
    Antioxidants (Basel); 2023 Jan; 12(2):. PubMed ID: 36829879
    [No Abstract]   [Full Text] [Related]  

  • 26. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
    Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
    BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Clinical and Laboratory Variables Associated with Cardiotoxicity Events Due to Doxorubicin in Breast Cancer Patients: A 1-Year Follow-Up Study.
    Simões R; Silva LM; de Oliveira AN; Alves MT; Pestana RMC; de Souza IDP; Oliveira HHM; Soares CE; Sabino AP; Gomes KB
    Cardiovasc Toxicol; 2021 Feb; 21(2):106-114. PubMed ID: 32844368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
    Ghigo A; Li M; Hirsch E
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-(1-7) reduces doxorubicin-induced cardiac dysfunction in male and female Sprague-Dawley rats through antioxidant mechanisms.
    Rahimi O; Kirby J; Varagic J; Westwood B; Tallant EA; Gallagher PE
    Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H883-H894. PubMed ID: 32083974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular Mechanisms Mediating Exercise-Induced Protection against Cardiotoxic Anthracycline Cancer Therapy.
    Dozic S; Howden EJ; Bell JR; Mellor KM; Delbridge LMD; Weeks KL
    Cells; 2023 May; 12(9):. PubMed ID: 37174712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.
    Jo A; Choi TG; Jo YH; Jyothi KR; Nguyen MN; Kim JH; Lim S; Shahid M; Akter S; Lee S; Lee KH; Kim W; Cho H; Lee J; Shokat KM; Yoon KS; Kang I; Ha J; Kim SS
    Antioxid Redox Signal; 2017 Jan; 26(2):70-83. PubMed ID: 27357096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiotoxicity and cardioprotection in childhood cancer.
    Lipshultz SE; Sambatakos P; Maguire M; Karnik R; Ross SW; Franco VI; Miller TL
    Acta Haematol; 2014; 132(3-4):391-9. PubMed ID: 25228565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity.
    Monahan DS; Flaherty E; Hameed A; Duffy GP
    Biomed Pharmacother; 2021 Aug; 140():111702. PubMed ID: 34015579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity.
    Wu BB; Leung KT; Poon EN
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The beneficial effects of reducing NLRP3 inflammasome activation in the cardiotoxicity and the anti-cancer effects of doxorubicin.
    Maayah ZH; Takahara S; Dyck JRB
    Arch Toxicol; 2021 Jan; 95(1):1-9. PubMed ID: 32852568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular disease in survivors of childhood cancer.
    Bansal N; Amdani SM; Hutchins KK; Lipshultz SE
    Curr Opin Pediatr; 2018 Oct; 30(5):628-638. PubMed ID: 30124579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity.
    An J; Sheikh MS
    Curr Cancer Drug Targets; 2019; 19(5):400-407. PubMed ID: 29189161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endothelial-to-Mesenchymal Transition: Potential Target of Doxorubicin-Induced Cardiotoxicity.
    Feng J; Wu Y
    Am J Cardiovasc Drugs; 2023 May; 23(3):231-246. PubMed ID: 36841924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance.
    Gyöngyösi M; Lukovic D; Zlabinger K; Spannbauer A; Gugerell A; Pavo N; Traxler D; Pils D; Maurer G; Jakab A; Riesenhuber M; Pircher A; Winkler J; Bergler-Klein J
    Cardiovasc Res; 2020 Apr; 116(5):970-982. PubMed ID: 31346605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.